Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16143783 | 0.86 | DYRK1B (0.43) | DYRK1BCLK1DYRK1ADYRK2PIP4K2A | |
| SCHEMBL1703193 | 0.86 | SGK1 (0.40) | DYRK1BCLK1DYRK1ADYRK2MAP2K4 | |
| SCHEMBL1702278 | 0.81 | IKBKB (0.40) | DYRK1BCLK1DYRK1ADYRK2PIP4K2A | |
| SCHEMBL2444702 | 0.80 | CYP3A4 (0.44) | DYRK1BCLK1DYRK1ADYRK2MAPK10 | |
| SCHEMBL12302429 | 0.79 | DYRK1B (0.38) | DYRK1BCLK1DYRK1ADYRK2PIP4K2A | |
| SCHEMBL1542770 | 0.74 | CYP3A4 (0.50) | — | |
| SCHEMBL1348856 | 0.73 | CYP3A4 (0.51) | PIP4K2APIP4K2BMAP2K4KIF11 | |
| SCHEMBL1348857 | 0.73 | CYP3A4 (0.51) | PIP4K2APIP4K2BMAP2K4KIF11 | |
| SCHEMBL1702563 | 0.73 | TDO2 (0.41) | — | |
| SCHEMBL1702496 | 0.72 | PIP4K2A (0.40) | DYRK1BCLK1DYRK1ADYRK2PIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | DYRK1B 4742/4885CLK1 4047/4885DYRK1A 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.